By targeting CBL-c, it may be possible to disrupt EGFR recycling and enhance lysosomal degradation, thereby inhibiting EGFR activation and potentially limiting tumor growth in NSCLC (Hong et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.